BLOG Archives | Page 15 of 15 | MicroGen Diagnostics

December 30, 2025

The Hidden Microbial Factor Behind 57% of Premature IUD Removals

A Critical Issue Affecting Millions of Women Intrauterine devices represent one of the most effective forms of long-acting reversible contraception available today, with efficacy rates comparable to sterilization methods. Yet despite their clinical advantages, a staggering 57% of IUD patients in the United States choose to have their devices removed before the recommended duration of use. This represents not just a contraceptive failure, but a missed opportunity to provide sustained, reliable reproductive health management to millions of women. For clinicians managing IUD patients, these premature removals translate into valuable clinical time spent addressing complications, counseling disappointed patients, and navigating alternative […]

January 23, 2026

The CMS 2026 Expansion: What the Shift of Revision Total Joint Arthroplasty into ASCs Really Means

A Structural Shift in Outpatient Orthopedics – and the Role of Diagnostics Beginning January 1, 2026, a fundamental shift will take place in outpatient orthopedic care. The Centers for Medicare & Medicaid Services (CMS) has finalized a rule expanding Ambulatory Surgical Center (ASC) eligibility to include select revision total knee and hip arthroplasty procedures. This decision moves some of the most complex orthopedic cases into outpatient settings for appropriately selected patients. While this policy change expands access and efficiency, it also raises the bar for diagnostic certainty. Revision arthroplasty carries inherently higher clinical risk-particularly related to occult infection-and the ASC environment allows far less tolerance for […]

January 27, 2026

The Clinician’s Guide to the Genomic Galaxy

DON’T PANIC The Clinician’s Guide to the Genomic Galaxy is designed to help you navigate the genomic landscape that is materializing beneath your feet as we speak. It is materializing quickly; we should learn to walk now so that we may run in the days ahead. When clinicians first encounter next-generation sequencing (NGS), or hear it discussed at conferences, the road is difficult to see through all the caution signs and while caution is certainly appropriate, these signs are often treated like “road closed” signs. Some of the cautionary statements that frequent discussions of molecular diagnostics are: NGS is too […]